81 related articles for article (PubMed ID: 23917689)
1. CD30-targeted therapy with brentuximab vedotin and DLI in a patient with T-cell posttransplantation lymphoma: induction of clinical remission and cellular immunity.
Theurich S; Wennhold K; Wedemeyer I; Rothe A; Hübel K; Shimabukuro-Vornhagen A; Holtick U; Hallek M; Scheid C; von Bergwelt-Baildon M
Transplantation; 2013 Aug; 96(3):e16-8. PubMed ID: 23917689
[No Abstract] [Full Text] [Related]
2. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission.
Theurich S; Malcher J; Wennhold K; Shimabukuro-Vornhagen A; Chemnitz J; Holtick U; Krause A; Kobe C; Kahraman D; Engert A; Scheid C; Chakupurakal G; Hallek M; von Bergwelt-Baildon M
J Clin Oncol; 2013 Feb; 31(5):e59-63. PubMed ID: 23269992
[No Abstract] [Full Text] [Related]
3. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
Younes A; Bartlett NL; Leonard JP; Kennedy DA; Lynch CM; Sievers EL; Forero-Torres A
N Engl J Med; 2010 Nov; 363(19):1812-21. PubMed ID: 21047225
[TBL] [Abstract][Full Text] [Related]
4. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK
Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550
[TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin in systemic T-cell lymphoma.
Oki Y; Younes A
Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
[TBL] [Abstract][Full Text] [Related]
6. T Cell PTLD Successfully Treated With Single-Agent Brentuximab Vedotin First-Line Therapy.
Choi M; Fink S; Prasad V; Anagnostopoulos I; Reinke P; Schmitt CA
Transplantation; 2016 Mar; 100(3):e8-e10. PubMed ID: 26900813
[No Abstract] [Full Text] [Related]
7. A Single-Center Experience With Brentuximab Vedotin in Gamma Delta T-Cell Lymphoma.
Talpur R; Chockalingam R; Wang C; Tetzlaff MT; Duvic M
Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):e15-9. PubMed ID: 26705678
[No Abstract] [Full Text] [Related]
8. Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy post-transplantation.
Koh KN; Im HJ; Suh JK; Lee SW; Choi ES; Seo JJ
Pediatr Blood Cancer; 2015 Jun; 62(6):1063-5. PubMed ID: 25641881
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
Mehra T; Ikenberg K; Moos RM; Benz R; Nair G; Schanz U; Haralambieva E; Hoetzenecker W; Dummer R; French LE; Guenova E; Cozzio A
JAMA Dermatol; 2015 Jan; 151(1):73-7. PubMed ID: 25317818
[TBL] [Abstract][Full Text] [Related]
10. Complete remission of refractory, ulcerated, primary cutaneous CD30+ anaplastic large cell lymphoma following brentuximab vedotin therapy.
Patsinakidis N; Kreuter A; Moritz RK; Stücker M; Altmeyer P; Möllenhoff K
Acta Derm Venereol; 2015 Feb; 95(2):233-4. PubMed ID: 24733422
[No Abstract] [Full Text] [Related]
11. Brentuximab vedotin.
Deng C; Pan B; O'Connor OA
Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
[TBL] [Abstract][Full Text] [Related]
12. [Brentuximab vedotin: new treatment for CD30+ lymphomas].
Terriou L; Bonnet S; Debarri H; Demarquette H; Morschhauser F
Bull Cancer; 2013; 100(7-8):775-9. PubMed ID: 23831822
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin for Hodgkin lymphoma who had failed allogeneic stem cell transplantation: a multicenter retrospective study.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):12-4. PubMed ID: 25768995
[No Abstract] [Full Text] [Related]
14. CD30-positive cutaneous T-cell lymphoma and response to Brentuximab Vedotin: 2 illustrative cases.
Mody K; Wallace JS; Stearns DM; Bowers G; Lacy SR; Levy NB; Zug KA; Lansigan F
Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):319-23. PubMed ID: 23313068
[No Abstract] [Full Text] [Related]
15. Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma.
Younes A
Hematol Oncol Clin North Am; 2014 Feb; 28(1):27-32. PubMed ID: 24287065
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.
Gualberto A
Expert Opin Investig Drugs; 2012 Feb; 21(2):205-16. PubMed ID: 22127011
[TBL] [Abstract][Full Text] [Related]
17. CD30-targeted antibody therapy.
Younes A
Curr Opin Oncol; 2011 Nov; 23(6):587-93. PubMed ID: 21986847
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma.
Garciaz S; Coso D; Peyrade F; Fürst S; Duran S; Chetaille B; Brenot-Rossi I; Devillier R; Granata A; Blaise D; Bouabdallah R
Hematol Oncol; 2014 Dec; 32(4):187-91. PubMed ID: 24301099
[TBL] [Abstract][Full Text] [Related]
19. Clinical roundtable monograph: CD30 in lymphoma: its role in biology, diagnostic testing, and targeted therapy.
Sotomayor EM; Young KH; Younes A
Clin Adv Hematol Oncol; 2014 Apr; 12(4 Suppl 10):1-22. PubMed ID: 24870054
[TBL] [Abstract][Full Text] [Related]
20. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies.
Fanale MA; Forero-Torres A; Rosenblatt JD; Advani RH; Franklin AR; Kennedy DA; Han TH; Sievers EL; Bartlett NL
Clin Cancer Res; 2012 Jan; 18(1):248-55. PubMed ID: 22080439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
